Gene Logic and Amersham Pharmacia Biotech K.K.Announce Japanese Business Development Collaboration
GAITHERSBURG, Md. and TOKYO, Sept. 26 /PRNewswire/ --Gene Logic Inc. (Nasdaq: GLGC), a leading provider of genomic information, and Amersham Pharmacia Biotech K.K., the Japanese subsidiary of Amersham Pharmacia Biotech Limited, announced today an alliance granting Amersham Pharmacia Biotech K.K. exclusive distribution rights to market and sell Gene Logic's products to the Japanese pharmaceutical and biotechnology market.
Under this exclusive partnership, Amersham Pharmacia Biotech K.K. will become the primary sales and marketing vehicle for the full range of Gene Logic's genomic information products in Japan. The products to be offered by Amersham Pharmacia Biotech K.K. will include the GeneExpress(TM)Suite, custom gene expression databases, gene discovery projects, and data management software tools and applications. Financial terms of the agreement were not disclosed.
"Amersham Pharmacia Biotech K.K. is delighted to be part of this very exciting opportunity. The technology provided by Gene Logic will play a pivotal role in helping Japanese pharmaceutical companies to accelerate their drug discovery and development processes in line with global standards," said Kazuo Takeuchi, Vice President at Amersham Pharmacia Biotech K.K. in Tokyo. "This alliance fits with Amersham Pharmacia Biotech K.K.'s business strategy and will help further strengthen our position in the genomics market in Japan."
"The combination of Gene Logic's leading edge genomic information and Amersham Pharmacia Biotech K.K.'s well established distribution network and well regarded reputation, provides a powerful platform for creating potential opportunities in the Japanese pharmaceutical and biotechnology communities," said Mark D. Gessler, President and Chief Executive Officer of Gene Logic. "This collaboration is further evidence of the steps we are taking in advancing our goal of establishing Gene Logic's genomic information products and technologies to researchers worldwide."
Amersham Pharmacia Biotech Overview
Amersham Pharmacia Biotech is at the frontier of new healthcare, providing the technologies to discover, develop and deliver therapies faster and more cost-effectively then ever before. Its technologies are used to uncover the structure and function of genes and proteins, screen molecules to discover potential new drugs and purify medical products such as insulin and blood plasma. Amersham Pharmacia Biotech, the life sciences division of Nycomed Amersham plc (London: NAM) (NYSE: NYE), is an international market leader in most of its markets. The customer base for the Amersham Pharmacia Biotech's products and technology are pharmaceutical and biotechnology companies and leading research and academic institutions in the United States, Europe, Latin America and Asia. For more information about Amersham Pharmacia Biotech, visit the company's Web site at apbiotech.com.
Gene Logic Overview
Gene Logic Inc. is a leading provider of genomic information, enabling the discovery and development of pharmaceutical, biotechnology, health care, and life science products through the systematic and industrialized application of genomics and bioinformatics. Gene Logic has built and is commercializing the world's most comprehensive survey of gene expression in human and animal tissues. Gene expression, which is the degree to which genes in a cell are switched on or off, or regulated, is information critical to understanding the functions of genes. Gene Logic markets two types of gene expression database products to the global pharmaceutical, biotechnology, health care and life science industries: its custom databases and related software products and its new GeneExpress Suite of databases. The GeneExpress Suite can be used to discover and validate novel drug targets, develop therapeutic compounds and facilitate clinical trials and patient management. Today, thirteen companies use Gene Logic's various gene expression products for drug discovery, predictive toxicology, diagnostic applications, and the identification of genes for agricultural applications.
For more information about Gene Logic, visit the company's Web site at genelogic.com or telephone toll-free on 1-800-GENELOGIC.
All statements in this press release that are not historical are considered forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Gene Logic's "expectations," "beliefs," "goals," "hopes," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Gene Logic from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, production, market acceptance, uncertainties related to cost and pricing of Gene Logic products, dependence on collaborative partners, uncertainties relating to sole source suppliers, competition, customer renewals and terminations, risks relating to intellectual property of Gene Logic and others, and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Gene Logic's Annual Report on Form 10-K for the year ended December 31, 1999 and Gene Logic's other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods.
SOURCE Gene Logic Inc.
CO: Gene Logic Inc., Amersham Pharmacia Biotech K.K.; Nycomed Amersham plc
ST: Japan, Maryland
IN: BIO FIN
SU:
09/26/2000 06:00 EDT prnewswire.com |
